Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

Testing the inflammation–insulin resistance link in clinical trials

Nature Reviews Rheumatology volume 9, pages 702–703 (2013)Cite this article

Subjects

Evidence of possible molecular crosstalk between inflammation and insulin resistance suggests that treatments for diabetes might be useful in patients with rheumatoid arthritis (RA), or vice versa. However, in a new trial of a PPARγ agonist in RA, the clinical effect was at most modest. So, does such an approach have a future?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ormseth, M. J. et al. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res. Ther. 15, R110 (2013).

    Article  Google Scholar 

  2. Freeman, D. J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51, 1596–1600 (2002).

    Article  CAS  Google Scholar 

  3. Wellen, K. E. & Hotamisligil, G. S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788 (2003).

    Article  CAS  Google Scholar 

  4. Hotamisligil, G. S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54 (Suppl. 2), S73–S78 (2005).

    Article  CAS  Google Scholar 

  5. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 342, d548 (2011).

  6. Stavropoulos-Kalinoglou, A. et al. Anti-tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012).

    Article  CAS  Google Scholar 

  7. Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).

    Article  CAS  Google Scholar 

  8. Douglas, K. M. J., Sattar, N. & Kitas, G. D. Potential role of statins and PPARs in rheumatoid arthritis. Future Rheumatol. 1, 259–274 (2006).

    Article  CAS  Google Scholar 

  9. Cariou, B., Charbonnel, B. & Staels, B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol. Metab. 23, 205–215 (2012).

    Article  CAS  Google Scholar 

  10. Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK

    Naveed Sattar

  2. Dudley Group NHS Foundation Trust, Russells Hall Hospital, Clinical Research Unit, Dudley, DY1 2HQ, UK

    George D. Kitas

Authors
  1. Naveed Sattar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George D. Kitas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George D. Kitas.

Ethics declarations

Competing interests

N. Sattar declares that he has consulted for AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Roche, Sanofi and UCB. G. D. Kitas declares that he has received speaker fees and/or consulting honouraria and/or research grants from Abbvie, AstraZeneca, BMS, Pfizer/Wyeth and UCB.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sattar, N., Kitas, G. Testing the inflammation–insulin resistance link in clinical trials. Nat Rev Rheumatol 9, 702–703 (2013). https://doi.org/10.1038/nrrheum.2013.178

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.178

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing